{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(2)"],"submitter":["Martino EA"],"funding":["Ministero della Salute"],"pubmed_abstract":["<h4>Background</h4>Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).<h4>Materials and methods</h4>This retrospective analysis included 247 Dara-R MM patients treated with EloPd. All patients were also refractory to lenalidomide, with 51.4% to a proteasome inhibitor, thus classified as triple-class refractory (TCR). Survival risk-scoring systems for PFS (progression-free risk score-PRS<sub>DaraR</sub>) and OS (survival risk score-SRS<sub>DaraR</sub>) were developed to stratify patients bas"],"journal":["ESMO open"],"pagination":["104084"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11761902"],"repository":["biostudies-literature"],"pubmed_title":["Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients."],"pmcid":["PMC11761902"],"pubmed_authors":["Brunori M","Mina R","Zamagni E","De Magistris C","Casaluci GM","Martino EA","Quaresima M","Bruzzese A","Tarantini G","Uccello G","Amendola A","Galli M","Rossini B","Sgherza N","Di Raimondo F","Gentile M","Petrucci MT","Morabito F","Ria R","Tripepi G","Rago A","Palumbo G","Pettine L","Franceschini L","Neri A","Fontana R","Califano C","Di Renzo N","Vincelli ID","Mele G","Palmieri S","Accardi F","Bertuglia G","Musso M","Gozzetti A","Mangiacavalli S","Nappi D","Cotzia E","Amico V","Mancuso K","Bongarzoni V","Offidani M","Della Pepa R","Conticello C","Musto P","Curci P","Vigna E","Barbieri E","Reddiconto G","Cerchione C","Derudas D","Zambello R","Rizzi R","Maroccia A","Barila G"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.","description":"<h4>Background</h4>Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).<h4>Materials and methods</h4>This retrospective analysis included 247 Dara-R MM patients treated with EloPd. All patients were also refractory to lenalidomide, with 51.4% to a proteasome inhibitor, thus classified as triple-class refractory (TCR). Survival risk-scoring systems for PFS (progression-free risk score-PRS<sub>DaraR</sub>) and OS (survival risk score-SRS<sub>DaraR</sub>) were developed to stratify patients bas","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-21T23:54:19.647Z","creation":"2025-04-05T19:20:37.994Z"},"accession":"S-EPMC11761902","cross_references":{"pubmed":["39778329"],"doi":["10.1016/j.esmoop.2024.104084"]}}